Ateriksen^®

Key advantages:

• Unique anti-inflammatory profile:reduces the production of pro-inflammatory cytokines and chemokines, reduces inflammation in lung tissue¹;
• Reduces the severity of intoxication and catarrhal symptoms in influenza, SARS, COVID-19²
• Low toxicity, favorable tolerance profile ¹.
• The possibility of joint use with antiviral and symptomatic drugs

¹  Based on the results of preclinical studies. Instructions for medical use of Atheriksen ^® , RU LP – 007921.;

²  Kalyuzhin O.V., Baranova A., Bagaeva M.I. A strategy for managing virus-induced inflammation in COVID-19. The results of a multicenter adaptive randomized double-blind placebo-controlled trial in outpatient patients// Infectious diseases. 2023; 21(1): 26–34.

The studies are presented in the public register of clinical trials (http://www.clinicaltrials.gov ), as well as in the GRLS registry (https://grls.rosminzdrav.ru /)